Global Tacrolimus Market Size, Share & Trends Analysis Report, By Type (Ointment, Capsules, and Injection), By Application (Hospitals, Clinics, and Others), Forecast (2022-2028)

The global tacrolimus market is anticipated to grow at a CAGR of 4.5% during the forecast period (2022-2028). Tacrolimus inhibits the initiation of serine-threonine phosphatase, calcineurin, in T lymphocytes. This suppresses T lymphocyte activation and the consequent generation of cytotoxic lymphocytes, thereby controlling the process that leads to organ rejection. Available in various dosage forms such as tablets, injections, and capsules, it is one of the most sold immunosuppressant drugs in the market. This medication works by supporting the body to accept the new organ and lower the risk of organ rejection to prevent the body from attacking and rejecting the transplanted organ which could be liver, kidney, or even heart. The growth of the market is attributed to the rising number of organ transplant among adult and pediatric patients globally.

For instance, as per the Organ Procurement and Transplantation Network (OPTN) 117,000+ number of men, women, and children were on the national transplant waiting list as of July 2017 in the US and 17,155 organ transplants were done so far in 2017. Further, tacrolimus is also used in treating certain dermatological conditions such as atopic dermatitis and psoriasis. Another key trend observed in the market is that people have become more conscious about dermatological issues. Thus, atopic dermatitis being a prevalent dermatological issue that requires substantial medical solution such as tacrolimus. Some forms of tacrolimus are available in generic form and are given orally or by injection. It contains calcineurin inhibitors that can stop the immune system from producing substances that may cause eczema.

Some key players operating in the market include GlaxoSmithKline plc, Astellas Pharma Inc., and Mylan NV, among others. The market players are focusing on several strategies, such as mergers and acquisitions, partnerships, product launches, and collaborations. For instance, in December 2020, Biocon Ltd. announced the launch of Tacrolimus capsules in the US. In November 2020, Lupin Ltd. announced the launch of Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg, after Lupin’s alliance partner Concord Biotech Ltd. (Concord) received an approval for its ANDA from the US Food and Drug Administration (US FDA). Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg, are the generic equivalent of Prograf Capsules, 0.5 mg, 1 mg, and 5 mg, of Astellas Pharma US, Inc., and are indicated for the prophylaxis of organ rejection, in adult patients receiving allogeneic kidney transplant, liver transplant, and heart transplant, and in pediatric patients receiving allogeneic liver transplants, in combination with other immunosuppressants.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-

• By Type
• By Application

• Regions covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape: GlaxoSmithKline plc, Astellas Pharma Inc., and Mylan NV, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

• Deviation from the pre-COVID-19 forecast
• Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Tacrolimus Market Report by Segment

By Type

• Ointment
• Capsules
• Injection

By Application

• Hospitals
• Clinics
• Others

Global Tacrolimus Market Report by Region

North America

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa